ATE174217T1 - Verwendung von leflunomid zur hemmung von interleukin 1 alpha - Google Patents
Verwendung von leflunomid zur hemmung von interleukin 1 alphaInfo
- Publication number
- ATE174217T1 ATE174217T1 AT94100012T AT94100012T ATE174217T1 AT E174217 T1 ATE174217 T1 AT E174217T1 AT 94100012 T AT94100012 T AT 94100012T AT 94100012 T AT94100012 T AT 94100012T AT E174217 T1 ATE174217 T1 AT E174217T1
- Authority
- AT
- Austria
- Prior art keywords
- alpha
- leflunomide
- inhibit interleukin
- interleukin
- inhibit
- Prior art date
Links
- 102000004125 Interleukin-1alpha Human genes 0.000 title abstract 2
- 108010082786 Interleukin-1alpha Proteins 0.000 title abstract 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000681 leflunomide Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4300276 | 1993-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE174217T1 true ATE174217T1 (de) | 1998-12-15 |
Family
ID=6477852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94100012T ATE174217T1 (de) | 1993-01-08 | 1994-01-03 | Verwendung von leflunomid zur hemmung von interleukin 1 alpha |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5554637A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0607774B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH06234638A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE174217T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE59407412D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0607774T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2124799T3 (cg-RX-API-DMAC7.html) |
| GR (1) | GR3029492T3 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011051A (en) * | 1996-07-31 | 2000-01-04 | Hoechst Aktiengesellschaft | Use of isoxazole and crotonamide derivatives for the modulation of apoptosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| DE3534440A1 (de) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| US5494911A (en) * | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
| DE69132470D1 (de) * | 1990-08-06 | 2000-12-21 | Chiron Corp | Verfahren zum nachweis von cytokinkonvertasehemmern |
| WO1992016226A1 (en) * | 1991-03-19 | 1992-10-01 | Smithkline Beecham Corporation | Il-1 inhibitors |
| US5292746A (en) * | 1991-09-12 | 1994-03-08 | Merrell Dow Pharmaceuticals Inc. | Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock |
| WO1995003297A1 (en) * | 1993-07-21 | 1995-02-02 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
-
1994
- 1994-01-03 EP EP94100012A patent/EP0607774B1/de not_active Expired - Lifetime
- 1994-01-03 DE DE59407412T patent/DE59407412D1/de not_active Expired - Lifetime
- 1994-01-03 ES ES94100012T patent/ES2124799T3/es not_active Expired - Lifetime
- 1994-01-03 DK DK94100012T patent/DK0607774T3/da active
- 1994-01-03 AT AT94100012T patent/ATE174217T1/de active
- 1994-01-07 JP JP6000424A patent/JPH06234638A/ja not_active Abandoned
-
1995
- 1995-06-05 US US08/462,916 patent/US5554637A/en not_active Expired - Lifetime
-
1999
- 1999-02-25 GR GR990400588T patent/GR3029492T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0607774B1 (de) | 1998-12-09 |
| ES2124799T3 (es) | 1999-02-16 |
| DK0607774T3 (da) | 1999-08-16 |
| GR3029492T3 (en) | 1999-05-28 |
| EP0607774A3 (cg-RX-API-DMAC7.html) | 1994-08-31 |
| EP0607774A2 (de) | 1994-07-27 |
| JPH06234638A (ja) | 1994-08-23 |
| US5554637A (en) | 1996-09-10 |
| DE59407412D1 (de) | 1999-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE174218T1 (de) | Verwendung von leflunomid zur hemmung von interleukin 1 beta | |
| DE59407414D1 (de) | Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha | |
| ATE88890T1 (de) | D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen. | |
| EP0735870A4 (en) | Use of pla 2? inhibitors as treatment for alzheimer's disease | |
| ATE81503T1 (de) | N-(mercaptoalkyl)-omega-hydroxyalkylamide und ihre verwendung als reduktionsmittel in einem verfahren zur bleibenden gestaltung von haaren. | |
| ATE68697T1 (de) | Verwendung von azolylmethyloxiranen zur bekaempfung von viralen erkrankungen. | |
| ATE63906T1 (de) | 3,5-disubstituierte 4,5-dihydroisoxazole als transglutaminasehemmer. | |
| DE69433501D1 (de) | Oxazole zur behandlung von zytokinvermittelten erkrankungen | |
| DK46789D0 (da) | 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf | |
| DE69021530D1 (de) | Neue Derivate von A-nor-3-Carboxysteroiden. | |
| ATE184792T1 (de) | 2-bromomelatonin zur behandlung von schlafstörungen | |
| ATE259640T1 (de) | Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung | |
| ATE174220T1 (de) | Verwendung von leflunomid zur hemmung von interleukin 8 | |
| ATE159424T1 (de) | Verwendung von hydroxylierte carbonsäure zur behandlung von nägeln | |
| DE3852935D1 (de) | Substituierte Alpha-Aminosäuren mit pharmazeutischer Aktivität. | |
| EA200001124A1 (ru) | Способ генной терапии | |
| ATE151407T1 (de) | Durch acylierung von proteinhydrolipaten dargestellte aminosäurederivate und antimikrobielle, antiparasitäre oder kosmetische zusammensetzungen die diese enthalten | |
| DE3854121D1 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
| MD960168A (ro) | Metodă şi compuşi pentru tratamentul infecţiilor virale | |
| DE3884895D1 (de) | Verwendung von Bezafibrat zur Behandlung von Diabetes. | |
| DE69029884D1 (de) | 5-Methylisoxazol-4-carbonsäure-anilide und 2-Hydroxyethyliden-cyanoessigsäure-anilide zur Behandlung von Augenkrankheiten | |
| ATE143804T1 (de) | Zusammensetzung zur behandlung von mastitis und metritis | |
| ATE174217T1 (de) | Verwendung von leflunomid zur hemmung von interleukin 1 alpha | |
| DE59305800D1 (de) | Werkzeug zur behandlung von oberflächen von bauteilen | |
| DE59504374D1 (de) | Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen |